(Refiles to correct paragraph 10 sourcing from AstraZeneca)
By Stanley Widianto
JAKARTA, April 8 (Reuters) - Indonesia is in talks with China to secure as many as 100 million COVID-19 vaccine doses to plug a gap in deliveries after delays in arrivals of AstraZeneca AZN.L shots, the health minister said on Thursday.
Indonesia would receive 20 million doses of the AstraZeneca vaccine via a bilateral deal in 2021, instead of 50 million initially agreed, Health Minister Budi Gunadi Sadikin told a parliamentary hearing.
The remaining 30 million doses were due to be shipped by the second quarter of 2022, he said.
Budi said the government had "embarked on a discussion with the Chinese government to ask for an additional 90-100 million (doses)".
"We're also asking for vaccines from the U.S. when they're done with their own vaccinations and sell their vaccines overseas."
Besides AstraZeneca, Indonesia relies heavily on vaccines produced by China's Sinovac Biotech SVA.O for inoculations which began in January. It aims to reach 181.5 million people within a year in a bid to reach herd immunity.
Sinovac has supplied about 56 million doses so far.
Indonesia was also due to receive 54 million doses of the AstraZeneca vaccine in phases via the COVAX sharing scheme, though Budi said Indian export restrictions would delay shipments in April.
"That's something that we cannot accept and we're negotiating with AstraZeneca. So that's 100 million doses of vaccine whose schedule remains unclear," he said.
In response, AstraZeneca Indonesia referred Reuters to an April 2 statement in which the company said it aimed to start first deliveries in June.
Indonesia has also launched a private vaccination programme for companies to buy government-procured vaccines for their staff.
State-owned company Bio Farma had started negotiations with China's Sinopharm and Cansino 6185.HK , along with the producer of Russia's Sputnik V, for vaccines for the private programme, Bio Farma chief executive Honesti Basyir told the parliamentary hearing.
The Southeast Asian country has been struggling to control one of Asia's worst epidemics, with 1.55 million cases and 42,200 deaths. It has administered at least one vaccine shot to more than 9.22 million people.
European and British regulators said on Wednesday they had found possible links between AstraZeneca's vaccine and very rare cases of blood clots, but reaffirmed the vaccine's importance in protecting people against COVID-19. (Additional Reporting by Nilufar Rizki Editing by Ed Davies, Nick Macfie)
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.